In one embodiment, the invention provides a method of regenerating organs and tissues in a subject suffering from one or more organ or tissue manifestations of glucose supply side associated metabolic syndrome, the method comprising: (a) confirming that the subject suffers from or is at risk for suffering from organ and/or tissue damage associated with a glucose supply side associated metabolic syndrome; and (b) co-administering to the subject an effective amount of a pharmaceutical composition comprising a first and optionally a second active composition, said first active composition comprising an ileal brake hormone releasing substance encapsulated within an enteric coating which releases said substance within said subject's ileum and ascending colon causing release of at least one ileal brake hormone from L-cells of said subject, said optional second active composition being formulated in immediate and/or early release form in an over coating onto said enteric coating, wherein said second composition is beneficial to at least one aspect of said subject's metabolic syndrome manifestations. Coadministration methods with a second pharmaceutical composition are also disclosed.

Described herein are novel compositions, targeted therapeutic methods, and assays for neutralizing and/or inhibiting the activity of oxazole-containing (OxC) compounds, to prevent or delay the onset of epithelial barrier dysfunction and chronic inflammation associated with various disorders, such as colitis.

The inventors have produced two high specificity and high affinity monoclonal antibodies that bind to human neuromedin U (NMU). Methods and compositions are provided for treating an individual in need thereof (e.g., an individual who is obese and/or has diabetes) by administering an anti-NMU/NMUR agent (e.g., an anti-NMU antibody). For example, methods and compositions are provided for increasing circulating insulin in an individual. Methods and compositions are also provided for detecting neuromedin U (NMU) (e.g., in a biological sample such as serum). Methods and compositions are also provided for predicting whether an individual will develop diabetes and/or PDAC, and for identifying an individual who would benefit from administration of an anti-NMU/NMUR agent.

The invention relates to an in vitro method for the diagnosis of acute pancreatitis (AP) in a subject by detection of Glycoprotein 2 isoform alpha (GP2a) protein. In particular the invention pro-vides an in vitro method for the diagnosis of acute pancreatitis (AP) in a subject by detection of Glycoprotein 2 isoform alpha (GP2a) protein, comprising providing a sample of a human subject exhibiting symptoms of having pancreatic disease, wherein said sample is obtained from the subject within 72 hours of the appearance of said symptoms, providing an affinity reagent directed against GP2a, contacting said sample with said affinity reagent thereby capturing GP2a from said sample, and determining the concentration of GP2a from said sample, wherein determining a concentration of GP2a in said sample that is greater than the average concentration of GP2a in control samples, such as in a group of healthy individuals, indicates the presence of AP and the absence of one or more of chronic pancreatitis, pancreatic cancer, gastrointestinal cancer, liver cancer, neuroendocrine tumor, sarcoma, peptic ulcer or peritonitis. The invention further provides a kit and a system developed for carrying out the claimed method and determining the concentration of GP2a and performing an automated analysis of one or more samples.

The present invention provides an antibody combination that can be used to detect regenerating islet-derived protein 1? (REGIA), each antibody in the antibody combination can specifically bind to REGIA with high affinity so as to form a double-antibody sandwich form, thereby enabling qualitative and quantitative detection of human REGIA. The antibody combination or an ELISA detection kit comprising the antibody combination can be used for auxiliary diagnosis or disease risk prediction of REGIA-related diseases.

The present disclosure includes compositions and methods for treating gastrointestinal inflammatory disease and/or cancers. In certain aspects, the disclosure includes an isolated cell comprising a nucleic acid vector comprising a gene encoding the transcription factor ZBTB20 which is operably linked to a promoter.

Disclosed are methods, systems, and apparatuses for non-invasive detection of colitis in a subject. The methods involve depositing a bodily fluid sample from the subject on an internal reflection element (IRE). A beam of infrared (IR) radiation can then be directed through the IRE under conditions such that the IR radiation interacts with the bodily fluid sample. An absorption spectrum can then be recorded over a range of preselected frequencies to detect peaks that are affected by colitis. In preferred embodiments, the methods and systems involve Fourier Transform Infrared Spectroscopy (FTIR).

The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.

A hybridoma cell line NM002-1 secreting an anti-human pancreatic cancer monoclonal antibody and deposited under CCTCC Accession NO: C201173. Also, an anti-human pancreatic cancer monoclonal antibody NJ002-1 secreted by the hybridoma cell line NM002-1 and use thereof.

The present invention is directed to a multi-sensor array compound including at least three chromophores, at least one receptor and an anchor. Contacting the compound of this invention with an analyte (such as carbohydrate) forms a complex with unique optical signature. The unique optical signature allows differentiating between carbohydrates, diagnosing diseases associated with the carbohydrate, and encoding information in an encoding system. ##STR00001##